Granite Point Capital Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Granite Point Capital Management’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-150,000	Closed	-$924K	–	101
2019 Q3	$924K	Hold	150,000	–	–	0.14%	48
2019 Q2	$2.49M	Sell	150,000 -50,000	-25%	-$868K	0.17%	39
2019 Q1	$3.34M	Sell	200,000 -200,000	-50%	-$2.88M	0.32%	35
2018 Q4	$4.59M	Buy	400,000 +180,500	+82%	+$3.65M	0.93%	20
2018 Q3	$8.78M	Buy	219,500 +184,250	+523%	+$5.24M	0.58%	26
2018 Q2	$997K	Sell	35,250 -102,225	-74%	-$2.27M	0.09%	74
2018 Q1	$2.1M	Buy	+137,475	New	+$3.27M	0.2%	33

Other funds holding MRNS

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return

Granite Point Capital Management's MRNS Position: Q4 2022 in Review

Granite Point Capital Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2022, closing a stake of 472,056 shares — an estimated $3.14M sold.

Granite Point Capital Management first reported a position in MRNS in Q1 2017 and held it in 23 quarters. The position peaked at $18.7M in Q2 2018. 74 funds tracked by Wall St. Rank hold MRNS as of Q4 2022.

Granite Point Capital Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2022 after selling out during the quarter.
Granite Point Capital Management sold 472,056 Marinus Pharmaceuticals, Inc shares in Q4 2022, an estimated $3.14M.
Granite Point Capital Management first reported a position in Marinus Pharmaceuticals, Inc in Q1 2017 and held it in 23 quarters.
Granite Point Capital Management's Marinus Pharmaceuticals, Inc position peaked at $18.7M in Q2 2018.
74 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2022.

Based on Granite Point Capital Management's 13F filing for Q4 2022, filed 7 Feb 2023.